Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) EPS (Basic) (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed EPS (Basic) for 4 consecutive years, with -$0.21 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Basic) rose 69.57% to -$0.21 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.04, a 3.7% increase, with the full-year FY2025 number at -$1.04, down 1.96% from a year prior.
  • EPS (Basic) was -$0.21 for Q4 2025 at Day One Biopharmaceuticals, down from -$0.19 in the prior quarter.
  • In the past five years, EPS (Basic) ranged from a high of $0.38 in Q3 2024 to a low of -$0.72 in Q1 2024.
  • A 4-year average of -$0.42 and a median of -$0.54 in 2022 define the central range for EPS (Basic).
  • Peak YoY movement for EPS (Basic): skyrocketed 170.37% in 2024, then plummeted 480.0% in 2025.
  • Day One Biopharmaceuticals' EPS (Basic) stood at -$0.56 in 2022, then fell by 14.29% to -$0.64 in 2023, then decreased by 7.81% to -$0.69 in 2024, then skyrocketed by 69.57% to -$0.21 in 2025.
  • Per Business Quant, the three most recent readings for DAWN's EPS (Basic) are -$0.21 (Q4 2025), -$0.19 (Q3 2025), and -$0.29 (Q2 2025).